Article
Medicine, General & Internal
Margaretha M. Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard
Summary: In adults with type 1 diabetes, switching from isCGM to rtCGM significantly improved time in range after 6 months of treatment, suggesting that clinicians should consider using rtCGM to enhance the health and quality of life of people with type 1 diabetes.
Article
Endocrinology & Metabolism
Georges Jabbour, Nicola Luigi Bragazzi
Summary: This study found that CGM use may be associated with increased vigorous physical activity among youth with T1D, while higher levels of hypoglycemia fear in children were correlated with activity level and episodes of hypoglycemia.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma
Summary: The study aimed to evaluate glycemic control in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system during Basalin or Lantus administration. Lantus-treated patients showed lower 24-hour MBG, MAGE, and SDBG compared to the Basalin group. Insulin glargine Lantus may be a better choice for T2DM patients with HbA1c <= 7%.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Clinical Neurology
Santhi N. Logel, Ellen L. Connor, David A. Hsu, Rachel J. Fenske, Neil J. Paloian, Darryl C. De Vivo
Summary: Glut1 deficiency syndrome is a genetic disorder that impairs glucose transport across the blood-brain barrier, leading to decreased brain metabolism. The standard treatment is the ketogenic diet, but alternative options are limited if patients do not respond to it.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Medicine, General & Internal
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, Pierre Gourdy, Soumitra Kar, Andre Vianna, Tina Vilsboll, Siri Vinther, Yiming Mu
Summary: Once-weekly insulin icodec may serve as a simpler alternative to daily basal insulin for patients with type 2 diabetes. In this study, once-weekly icodec demonstrated superior reduction in HbA1c compared to once-daily degludec after 26 weeks of treatment in insulin-naive type 2 diabetes patients, with no difference in weight change but a slightly higher rate of combined level 2 or 3 hypoglycemic events.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, Pierre Gourdy, Soumitra Kar, Andre Vianna, Tina Vilsboll, Siri Vinther, Yiming Mu
Summary: Once-weekly insulin icodec could be a simpler dosing alternative to daily basal insulin for type 2 diabetes patients. The study compared the efficacy and safety of once-weekly icodec with once-daily insulin degludec and found that icodec was superior in reducing HbA1c levels after 26 weeks, with no difference in weight change but a slightly higher rate of hypoglycemic events in the icodec group.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Endocrinology & Metabolism
Julie Maria Boggild Brosen, Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Georg Riber Hedetoft, Tonny Joran Jensen, Charlotte Ron Stolberg, Claus Bogh Juhl, Susanne Sogaard Lerche, Kirsten Norgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard
Summary: In individuals with type 1 diabetes prone to nocturnal severe hypoglycemia, insulin degludec demonstrates a significant reduction in nocturnal CGM-recorded hypoglycemia compared to insulin glargine U100, primarily due to a decrease in asymptomatic hypoglycemia.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Stephanie R. Johnson, Deborah J. Holmes-Walker, Melissa Chee, Arul Earnest, Timothy W. Jones
Summary: Following the national subsidy, there was a significant increase in CGM use, which was associated with sustained improvement in glycemic control. This study provides important information for economic analyses, future policy-making, and evaluation of diabetes technologies.
Article
Endocrinology & Metabolism
Stephanie R. Johnson, Deborah J. Holmes-Walker, Melissa Chee, Arul Earnest, Timothy W. Jones
Summary: After the national subsidy, the uptake of CGM increased significantly and was associated with sustained improvement in glycemic control.
Article
Medicine, General & Internal
Lalantha Leelarathna, Mark L. L. Evans, Sankalpa Neupane, Gerry Rayman, Sarah Lumley, Iain Cranston, Parth Narendran, Katharine Barnard-Kelly, Christopher J. J. Sutton, Rachel A. A. Elliott, Vicky P. P. Taxiarchi, Georgios Gkountouras, Matthew Burns, Womba Mubita, Naresh Kanumilli, Maisie Camm, Hood Thabit, Emma G. G. Wilmot
Summary: This study investigated the efficacy of intermittently scanned continuous glucose monitoring in patients with type 1 diabetes. The results showed that compared to traditional fingerstick testing, the use of intermittently scanned continuous glucose monitoring significantly reduced glycated hemoglobin levels and improved blood glucose control.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Endocrinology & Metabolism
Ramzi A. Ajjan, Simon R. Heller, Colin C. Everett, Armando Vargas-Palacios, Ruchi Higham, Linda Sharples, Diana A. Gorog, Alice Rogers, Catherine Reynolds, Catherine Fernandez, Pedro Rodrigues, Thozhukat Sathyapalan, Robert F. Storey, Deborah D. Stocken
Summary: This study analyzed the impact of modern glucose-monitoring strategies on glycemic and patient-related outcomes in individuals with type 2 diabetes (T2D) and recent myocardial infarction (MI). The results showed that compared with self-monitoring of blood glucose (SMBG), intermittently scanned continuous glucose monitoring (isCGM) marginally increased time in range and significantly reduced hypoglycemic exposure in T2D individuals with MI, while equally improving HbA(1c). These findings explain the cost effectiveness of isCGM.
Article
Endocrinology & Metabolism
Shoubi Wang, Zhenhua Tan, Ting Wu, Qingbao Shen, Peiying Huang, Liying Wang, Wei Liu, Haiqu Song, Mingzhu Lin, Xiulin Shi, Xuejun Li
Summary: Nocturnal asymptomatic hypoglycemia (NAH) is a serious complication of diabetes that is difficult to detect clinically. This study found that high glycemic variability is strongly associated with the risk of NAH. The largest amplitude of glycemic excursion (LAGE) based on self-monitoring blood glucose (SMBG) can be an independent predictor of NAH for outpatients with type 2 diabetes, and an LAGE greater than 3.48 mmol/L may serve as a warning for a high risk of NAH in daily life.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Michael A. Rotondi, Octavia Wong, Michael Riddell, Bruce Perkins
Summary: Universal use of CGM or isCGM in the Canadian T1D population is expected to reduce diabetes-related complications and mortality at an acceptable cost-effectiveness threshold.
Article
Public, Environmental & Occupational Health
Keyu Guo, Jiaqi Li, Liyin Zhang, Jianan Ye, Li Fan, Zhiyi Ding, Qin Zhou, Xia Li, Lin Yang, Zhiguang Zhou
Summary: This study compared the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy in Chinese patients with type 1 diabetes mellitus (T1DM). The results showed that CSII therapy was associated with lower HbA1c levels and better glycemic outcomes. However, it did not improve the risk of hypoglycemia.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Yannis Preau, Martine Armand, Sebastien Galie, Pauline Schaepelynck, Denis Raccah
Summary: Switching from FSL to DG4 led to improved glycemic control, reduced hypoglycemia, and decreased glucose variability, with sustained benefits observed after 3 months of using DG4.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Article
Endocrinology & Metabolism
Wendy S. Lane, Elena Favaro, Naveen Rathor, Hak C. Jang, Maiken I. S. Kjaersgaard, Alejandra Oviedo, Ludger Rose, Peter Senior, Giorgio Sesti, Alfonso Soto Gonzalez, Edward Franek
Article
Endocrinology & Metabolism
Wendy Lane, Elena Favaro, Esteban Jodar, Pranav Kelkar, Alejandra Oviedo, Ramsathish Sivarathinasami, Peter A. Senior, Giorgio Sesti, Edward Franek
Summary: The study found that faster aspart provides effective glucose control and improved postprandial glucose control compared to IAsp in patients with type 2 diabetes. It also showed comparable or improved rates of hypoglycemia, especially in patients with good glucose control, the elderly, and those with insulin resistance.
Article
Medicine, General & Internal
Chantal Mathieu, Bjorg Asbjornsdottir, Harpreet S. Bajaj, Wendy Lane, Ana Laura S. A. Matos, Sreenivasa Murthy, Karolina Stachlewska, Julio Rosenstock
Summary: The ONWARDS 4 trial aimed to compare the efficacy and safety of once-weekly insulin icodec with once-daily insulin glargine U100 in individuals with long-standing type 2 diabetes. The results showed that icodec demonstrated similar improvements in glycaemic control compared to glargine U100, with fewer basal insulin injections and no increase in hypoglycaemic rates. The trial had limitations including its relatively short duration and open-label design.